23:50 , Aug 8, 2018 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Cardiovascular Mouse studies suggest inhibiting the integrin CD29 could help treat vascular leakage caused by endotoxemia associated with sepsis. In a lipopolysaccharide (LPS)-induced mouse model of endotoxemia, an anti-CD29 mAb decreased vascular leakage and increased...
21:52 , Jul 13, 2018 |  BioCentury  |  Strategy

Roche’s partnering priority

As James Sabry gets set to lead partnering for all of Roche pharma, his first order of business might be to build out the company’s late-stage pipeline ahead of an impending patent cliff that puts...
16:49 , Feb 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Inflammation; infectious disease

INDICATION: Inflammatory disease; sepsis In vitro and mouse studies suggest inhibiting the MAC-1-CD40L interaction could help treat systemic inflammatory response syndrome (SIRS) and sepsis. In a mouse cell-based assay, a mAb against the M7 motif ligand-binding...
17:07 , Nov 8, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Multiple myeloma (MM) Patient sample, cell culture and mouse studies suggest chimeric antigen receptor (CAR) T cells targeting integrin β7 could help treat MM. In bone marrow samples from patients, co-culture with CAR T cells...
23:52 , Nov 6, 2017 |  BC Extra  |  Preclinical News

Team identifies new target for MM CAR T therapy

In a paper published in Nature Medicine, researchers at Osaka University and colleagues identified activated integrin beta(7) as a new target for a chimeric antigen receptor (CAR) T cell therapy for multiple myeloma, demonstrating that...
19:30 , Sep 11, 2017 |  BC Innovations  |  Distillery Techniques

Drug delivery

TECHNOLOGY: Nanoparticles Integrin β3-targeted nanoparticles could deliver chemotherapies to treat bone metastases of breast cancer. The nanoparticles consist of phospholipid/polysorbate 80 micelles loaded with drug and coated with an integrin αvβ3 (CD51/CD61)-binding quinolone analog. In patient...
21:45 , May 12, 2017 |  BioCentury  |  Strategy

Vertical vision

Shire plc’s deal with Parion Sciences Inc. is a step toward building vertically in ophthalmics, much like it has done in hereditary angioedema and hemophilia. On May 1, Shire gained exclusive, worldwide rights to P-321...
18:50 , May 1, 2017 |  BC Extra  |  Company News

Shire, Parion in deal for ENaC inhibitor for dry eye

Parion Sciences Inc. (Durham, N.C.) granted Shire plc (LSE:SHP; NASDAQ:SHPG) exclusive, worldwide rights to P-321 ophthalmic solution, an epithelial sodium channel (ENaC) inhibitor in development to treat dry eye disease. Parion received $20 million up front...
15:21 , Mar 21, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Tissue markers Tumor levels of integrin β4 could help predict outcomes in lung, ovarian, gastric and breast cancers. In tumor samples from 461 lung, 143 serous ovarian and 641 gastric cancer patients, high levels of...
14:57 , Mar 8, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Zebrafish studies suggest inhibiting TGFβ1 or LFA-1 could help treat metastatic breast cancer. In patient samples, levels of TGFβ1 were higher in primary tumors than in surrounding normal tissue. In two xenograft zebrafish...